Belite Bio, Inc
BLTE
Kedudukan dalam Saham
#2971
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Harga Saham
$153.69
Modal Pasaran
$6.19B
Perubahan (1 hari)
-0.49%
Perubahan (1 tahun)
67.05%
Negara
US
Perdagangan Belite Bio, Inc (BLTE)
Kategori
Healthcare
Sejarah harga saham bagi Belite Bio, Inc (BLTE)
Harga penutupan tertinggi: $154.31 pada 2026-10-01
Harga penutupan terendah: $10.59 pada 2022-04-01
Harga penutupan terendah: $10.59 pada 2022-04-01
Sejarah harga saham Belite Bio, Inc dari 2022 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 1.18% |
| 2025 | 137.93% |
| 2024 | 45.90% |
| 2023 | 43.40% |
| 2022 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $525.40 | 23.25% |
US
|
|
| $251.67 | 815.50% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $889.47 | 6.56% |
NL
|
|
| $752.87 | 7.40% |
CH
|
